Words of wisdom: Re: Adjuvant androgen deprivation for high-risk prostate cancer after radical prostatectomy: SWOG S9921 study.

摘要

The Southwest Oncology Group (SWOG) reports the largest experience of androgen deprivation therapy (ADT) adjuvant to radical prostatectomy (RP) for patients with high-risk prostate cancer (HRPCa). The SWOG 9921 randomly assigned HRPCa patients after RP to receive ADT for 24 mo or ADT in combination with mitoxantrone. The trial included patients in complete remission (prostate-specific antigen [PSA] < 0.2 ng/ml) with one of the following: Gleason score >7, preoperative PSA > 15 ng/ml, stage pT3b-T4, Nl, or the combination of Gleason score of 7 with either PSA >10 ng/ml or a positive margin.